Ask-Teva enteric tablets 100 mg 30 pcs — Made in Czech Republic — Free Delivery

ASK-Teva tablets are indicated for the secondary prevention of stroke.

To reduce your risk:

For prevention:

thrombosis and embolism after vascular surgery (percutaneous transluminal catheter angioplasty (PTCA), carotid endarterectomy, coronary artery bypass grafting (CABG), arteriovenous bypass grafting);

deep vein thrombosis and pulmonary embolism after prolonged immobilization (after surgery);

myocardial infarction in patients with a high risk of developing cardiovascular complications (diabetes mellitus, controlled arterial hypertension) and persons with a multifactorial risk of cardiovascular diseases (hyperlipidemia, obesity, smoking, old age, etc.).

Active ingredient: acetylsalicylic acid.

1 tablet contains 75 mg or 100 mg acetylsalicylic acid.

Excipients: microcrystalline cellulose (type 102), corn starch, colloidal silicon dioxide, stearic acid.

Shell: methacrylate copolymer dispersion, polysorbate 80, sodium lauryl sulfate, triethyl citrate, talc.

Hypersensitivity to acetylsalicylic acid, other salicylates, or any component of the preparation.

Chronic asthma caused by a history of salicylates or NSAIDs.

Acute peptic ulcers.

Hemorrhagic diathesis.

Severe renal failure.

Severe liver failure.

Severe heart failure.

Combination with methotrexate at a dose of 15 mg / week or more.

Administered orally.

The tablets should be swallowed whole with plenty of liquid (1/2 glass of water). The tablets should not be crushed, cut or chewed, since the enteric-coated tablet prevents the irritating effect of the preparation on the intestines.

To reduce the risk of death in patients with suspected acute myocardial infarction, use the preparation at a dose of 75-300 mg per day. For 30 days after a heart attack, continue to take a maintenance dose of 75-300 mg per day. After 30 days, further prevention of recurrent myocardial infarction should be considered.

Salicylates should be used with caution during the first and second trimesters of pregnancy. The use of salicylates is contraindicated during the third trimester of pregnancy.

The preparation is not intended for use in children.

No studies have been conducted.

Symptoms of severe poisoning may develop slowly, for example within 12-24 hours after application. After oral administration of a dose of ASA up to 150 mg / kg of body weight, the development of moderate intoxication is possible, and with a dose of> 300 mg / kg of body weight, severe intoxication.

Chronic salicylate poisoning can be latent, since its symptoms are nonspecific. Moderate chronic intoxication is observed, as a rule, only after repeated doses of large doses.

Acute intoxication is indicated by a pronounced change in the acid-base balance, which may differ depending on the patient's age and the severity of intoxication. Metabolic acidosis is a common manifestation in children. The severity of the condition cannot be assessed solely on the basis of the concentration of salicylates in the blood plasma. The absorption of acetylsalicylic acid can be slowed down due to a delay in gastric release, the formation of calculi in the stomach, or in the case of taking the preparation in the form of enteric-coated tablets.

In spontaneous reports, there was information about other adverse reactions for all dosage forms of ASA, including with oral short-term and long-term therapy, therefore, the definition of frequency categories according to CIOMS III is impossible.

In patients with severe forms of glucose-6-phosphate dehydrogenase deficiency, hemolysis and hemolytic anemia were observed.

Through the antiaggregatory effect, the use of ASA can increase the risk of bleeding. Hemorrhages such as PERIOPERATIVE bleeding, hematoma, epistaxis, urogenital bleeding, bleeding from the gums have been observed. Symptoms may continue for 4-8 days after discontinuation of acetylsalicylic acid.

Rarely or very rarely, serious bleeding was observed, such as gastrointestinal bleeding, hemorrhagic stroke, especially in patients with uncontrolled arterial hypertension and / or in the case of the simultaneous use of anticoagulants, which in some cases can potentially be life-threatening.

When used with methotrexate at a dose of 15 mg / week or more, the hematological toxicity of methotrexate increases (due to a decrease in the renal clearance of methotrexate by anti-inflammatory agents and the displacement of methotrexate by salicylates from its connection with plasma proteins).